RaQualia Pharma Inc. – Product Pipeline Review

Global Markets Direct’s, ‘RaQualia Pharma Inc. – Product Pipeline Review – 2016’, provides an overview of the RaQualia Pharma Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by RaQualia Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of RaQualia Pharma Inc.

The report provides overview of RaQualia Pharma Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses RaQualia Pharma Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features RaQualia Pharma Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate RaQualia Pharma Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for RaQualia Pharma Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RaQualia Pharma Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

RaQualia Pharma Inc. Snapshot 5

RaQualia Pharma Inc. Overview 5

Key Information 5

Key Facts 5

RaQualia Pharma Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

RaQualia Pharma Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

RaQualia Pharma Inc. - Pipeline Products Glance 11

RaQualia Pharma Inc. - Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

RaQualia Pharma Inc. - Clinical Stage Pipeline Products 12

Phase I Products/Combination Treatment Modalities 12

RaQualia Pharma Inc. - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

RaQualia Pharma Inc. - Drug Profiles 15

tegoprazan 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

RQ-00000010 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

RQ-00310941 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

RQ-00000774 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

RQ-00201894 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

RQ-00202730 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

RQ-00203066 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

RQ-00203078 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

RQ-00433412 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecule to Block Cav3.2 for Neuropathic Pain 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecules to Block Nav1.7 Sodium Channel for Pain 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecules to Block Nav1.8 Sodium Channel for Pain 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

RQ-00434739 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule for Pain 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule for Undisclosed Indication 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

RaQualia Pharma Inc. - Pipeline Analysis 30

RaQualia Pharma Inc. - Pipeline Products by Target 30

RaQualia Pharma Inc. - Pipeline Products by Route of Administration 32

RaQualia Pharma Inc. - Pipeline Products by Molecule Type 33

RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action 34

RaQualia Pharma Inc. - Recent Pipeline Updates 36

RaQualia Pharma Inc. - Dormant Projects 40

RaQualia Pharma Inc. - Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

List of Tables

RaQualia Pharma Inc., Key Information 5

RaQualia Pharma Inc., Key Facts 5

RaQualia Pharma Inc. – Pipeline by Indication, 2016 8

RaQualia Pharma Inc. – Pipeline by Stage of Development, 2016 9

RaQualia Pharma Inc. – Monotherapy Products in Pipeline, 2016 10

RaQualia Pharma Inc. – Phase III, 2016 11

RaQualia Pharma Inc. – Phase I, 2016 12

RaQualia Pharma Inc. – Preclinical, 2016 13

RaQualia Pharma Inc. – Discovery, 2016 14

RaQualia Pharma Inc. – Pipeline by Target, 2016 31

RaQualia Pharma Inc. – Pipeline by Route of Administration, 2016 32

RaQualia Pharma Inc. – Pipeline by Molecule Type, 2016 33

RaQualia Pharma Inc. – Pipeline Products by Mechanism of Action, 2016 35

RaQualia Pharma Inc. – Recent Pipeline Updates, 2016 36

RaQualia Pharma Inc. – Dormant Developmental Projects,2016 40

RaQualia Pharma Inc., Other Locations 41

RaQualia Pharma Inc., Subsidiaries 41

List of Figures

List of Figures

RaQualia Pharma Inc. – Pipeline by Top 10 Indication, 2016 7

RaQualia Pharma Inc. – Pipeline by Stage of Development, 2016 9

RaQualia Pharma Inc. – Monotherapy Products in Pipeline, 2016 10

RaQualia Pharma Inc. – Pipeline by Top 10 Target, 2016 30

RaQualia Pharma Inc. – Pipeline by Route of Administration, 2016 32

RaQualia Pharma Inc. – Pipeline by Molecule Type, 2016 33

RaQualia Pharma Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 34

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports